Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 1 synthesis or guideline pooled it, 122 citations in OpenAlex.
- Pathologic complete response in patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: A systematic review and meta-analysis.Cancer medicine · 2024Pooled it
- PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis.British journal of cancer · 2026Trial
- Induction chemotherapy plus chemoradiotherapy in esophageal cancer: long-term results and exploratory analyses of a randomized controlled trial.The oncologist · 2025Trial
- Phase I/II Trial of Perioperative Avelumab in Combination With Chemoradiation in the Treatment of Stage II/III Resectable Esophageal and Gastroesophageal Junction Cancer.Journal of surgical oncology · 2025Trial
- Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: A Phase II Study.Cancer medicine · 2025Trial
- Dose escalation based onRadiation oncology (London, England) · 2022Trial
- Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]).European journal of cancer (Oxford, England : 1990) · 2021Trial
- Trial
- Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial.Targeted oncology · 2018Trial
- Comparing the utility of FDG PET-CT and contrast-enhanced CT in patients with oesophagogastric adenocarcinoma treated with neoadjuvant chemotherapy.European radiology · 2026Article
- The Impact of Lung and Heart Radiation Dose During Preoperative Chemoradiation on Overall Survival in Esophageal Cancer-A Post Hoc Analysis of CALGB 80803 (Alliance).International journal of radiation oncology, biology, physics · 2026Article
- Article
- A new perspective on radiotherapy in the comprehensive treatment of cancer.Precision radiation oncology · 2026Review
- Perspectives on the Current Role of Radiation in the Management of Gastroesophageal Adenocarcinomas.Cureus · 2026Review
- Practice of radiation therapy for squamous cell esophageal cancer in Austria - a survey on behalf of the ÖGRO-GIT.Radiation oncology (London, England) · 2026Article
- Long-term Oncologic Outcomes Following Pathologic Complete Response for Esophageal Cancer.Annals of surgical oncology · 2026Article
- Article
- Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation for Esophageal Adenocarcinoma: A National Cancer Database Analysis.Annals of surgical oncology · 2026Article
- Apples, Oranges, and ESOPEC Recurrence Patterns.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
18 authors at 13 institutions in 1 country.
Funding
Abstract
purposeTo evaluate the use of early assessment of chemotherapy responsiveness by positron emission tomography (PET) imaging to tailor therapy in patients with esophageal and esophagogastric junction adenocarcinoma.
methodsAfter baseline PET, patients were randomly assigned to an induction chemotherapy regimen: modified oxaliplatin, leucovorin, and fluorouracil (FOLFOX) or carboplatin-paclitaxel (CP). Repeat PET was performed after induction; change in maximum standardized uptake value (SUV) from baseline was assessed. PET nonresponders (< 35% decrease in SUV) crossed over to the alternative chemotherapy during chemoradiation (50.4 Gy/28 fractions). PET responders (≥ 35% decrease in SUV) continued on the same chemotherapy during chemoradiation. Patients underwent surgery at 6 weeks postchemoradiation. Primary end point was pathologic complete response (pCR) rate in nonresponders after switching chemotherapy.
resultsTwo hundred forty-one eligible patients received Protocol treatment, of whom 225 had an evaluable repeat PET. The pCR rates for PET nonresponders after induction FOLFOX who crossed over to CP (n = 39) or after induction CP who changed to FOLFOX (n = 50) was 18.0% (95% CI, 7.5 to 33.5) and 20% (95% CI, 10 to 33.7), respectively. The pCR rate in responders who received induction FOLFOX was 40.3% (95% CI, 28.9 to 52.5) and 14.1% (95% CI, 6.6 to 25.0) in responders to CP. With a median follow-up of 5.2 years, median overall survival was 48.8 months (95% CI, 33.2 months to not estimable) for PET responders and 27.4 months (95% CI, 19.4 months to not estimable) for nonresponders. For induction FOLFOX patients who were PET responders, median survival was not reached.
conclusionEarly response assessment using PET imaging as a biomarker to individualize therapy for patients with esophageal and esophagogastric junction adenocarcinoma was effective, improving pCR rates in PET nonresponders. PET responders to induction FOLFOX who continued on FOLFOX during chemoradiation achieved a promising 5-year overall survival of 53%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.